Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WSD0628 and Radiation Therapy for Recurrent High-Grade Glioma
NCT05917145Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jan 2024
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of WSD0628 in glioblastoma (GBM) and astrocytoma (3 arms), sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose. Started Jan 2024; status: recruiting.
02
Drugs
WSD0628
03
Conditions
glioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on NCT05917145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05917145.